<code id='C4546366E2'></code><style id='C4546366E2'></style>
      • <acronym id='C4546366E2'></acronym>
      <center id='C4546366E2'><center id='C4546366E2'><tfoot id='C4546366E2'></tfoot></center><abbr id='C4546366E2'><dir id='C4546366E2'><tfoot id='C4546366E2'></tfoot><noframes id='C4546366E2'>
      • <optgroup id='C4546366E2'><strike id='C4546366E2'><sup id='C4546366E2'></sup></strike><code id='C4546366E2'></code></optgroup>
        5. <b id='C4546366E2'><label id='C4546366E2'><select id='C4546366E2'><dt id='C4546366E2'><span id='C4546366E2'></span></dt></select></label></b><u id='C4546366E2'></u>
          <i id='C4546366E2'><strike id='C4546366E2'><tt id='C4546366E2'><pre id='C4546366E2'></pre></tt></strike></i>
           


   

   

   
   
   
   
   
   
   
   
   
   
   
   
   

   
   
   
   
   
   
   
  
           
  
           
  
           
   
           
    
           
     
           
      
           
       
      
           
      
           
       
           
        
           
         
           
           
          
           
         
           
         
           
           
          
           
         
           
          
        
           
       
           
       
           
        
           
        
           
        
           
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
       
           
       
           
        
           
        
          
          00:00 
        
           
       
           
       
           
      
           
      
           
        
        
        
       
           
        00:00 
         
        00:00 
        LIVE 
       
           
        
       
           
        
           
        
           
        
           
        
           
       
           
       
           
       
           
        
        
        
        
        
        
        
        
        
      
           
       
    
    
      
           
       
           
      
           
     
           
     
           
       
     
           
     
           
      
           
      
           
      
           
      
           
       
           
      
           
      
           
      
           
       
           
       
          
         buffering 
       
           
      
           
      
           
       
           
        
           
        
          
          Replay 
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
        
           
        
           
        
           
       
           
      
           
      
           
      
           
      
           
      
           
       
           
      
           
     
           
     
           
      
           
     
           
     
           
      
           
       
           
        
           
       
           
       
           
        
          
          LIVE 
        
           
        00:00 
         /  
        00:00 
       
           
       
           
        
           
        
           
        
           
         
           
         
           
         
           
         
           
         
           
         
           
        
           
        
           
        
           
       
           
       
           
        
           
        
          
          LIVE 
        
           
       
           
       
           
        
           
        
          
          CC 
        
           
       
           
       
           
        
           
       
           
       
           
       
           
        
           
        
           
         
           
        
           
       
           
       
           
        
           
       
           
      
           
      
           
       
           
        
           
        
           
         
           
         
           
         
           
          
           
          
           
          
           
         
           
        
           
       
           
      
           
      
           
       
           
     
       
           
    
       
           
       
    
  
       
           
   
       
           
       
       
           
      
           
      
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       Opacity : 
        
      
           
     
           
     
           
     
           
      
           
  
     
           
    
           
    
           
    
           
     
          
       Share: 
     
           
      
     
           
      
      Copy 
     
           
      
    
           
    
          
      Close 
      
    
           
    
           
      
    
           
    
           
   
           
  
           
  
           
    
    
    
   
           
   
           
 
    
   
           
   
           
   
           
    
           
     
           
      
           
       
           
        
           
          
          
         
          
          entertainment 

          
          
            
          
          

           
           
        
           
       
           
      
           
     
           
    
           
    
           
     
           
      
           
      
           

                       
          Wikipedia  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      -
 
browse：761
                                  
                                    
          
                                    
            
          
 
          Several amyloid plaques forming between neurons in a brain
          Amyloid plaques forming between neurons. 																									Adobe
          The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.
          The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.
          advertisement
          Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
           
 
 
          

                              
          
                                 Previous article：

                                
                                          Anesthesiologist group: stop taking Ozempic before surgery
                                
                            
          Next article：  
                                      
                                          How to protect coverage of PrEP
                                                                    
          

      
           
      
           
        
           
                                               
        
           focus 
           
                   
      
           
  
  
          
    
          
        
          
            
          
                                                     
                
          Wikipedia
          
                            
          
        
          
        
    
          

          

    

      
           
     
           


   
    
           
   
           
  
 

  
           
    
           
           
           
            
            Back To Top 
           
           
           
           

            
           
                                                                    
                 
          focus
           
                                      
            
           
          
           
                                                          
             
          explore
           
                             
            
           
            
           

                                                         
             
          focus
           
               
              
            
           
            
           
                                                         
             
          focus
           
                             
      
           
 
     
           
     
           
      
          
              PhysicianCaitlinBernard,left,sitsbetweenattorneysJohnHooverandAliceMoricalonMay25,2023,beforeahearin
             
           
      
          
        © 2013-2023.Company name All rights reserved.Site Map 
         WSS-More Templates  
             Guangdong ICP4name